Despite manifold advances in cancer care during recent times, the outlook for many patients with epithelial and mesenchymal malignancies remains poor. Hence, as cancer diagnosis and management moves into the 21st century, cancer has become the paradigm disease of the molecular era, with a burgeoning body of research into aspects of cell biology amenable to earlier molecular diagnosis and efficacious treatment.
